The DOI matches its Crossref record; 352 of the 352 references it cites were found in a registry or an index.
Fibroblast growth factors and their receptors in cancer
Abstract
FGFs (fibroblast growth factors) and their receptors (FGFRs) play essential roles in tightly regulating cell proliferation, survival, migration and differentiation during development and adult life. Deregulation of FGFR signalling, on the other hand, has been associated with many developmental syndromes, and with human cancer. In cancer, FGFRs have been found to become overactivated by several mechanisms, including gene amplification, chromosomal translocation and mutations. FGFR alterations are detected in a variety of human cancers, such as breast, bladder, prostate, endometrial and lung cancers, as well as haematological malignancies. Accumulating evidence indicates that FGFs and FGFRs may act in an oncogenic fashion to promote multiple steps of cancer progression by inducing mitogenic and survival signals, as well as promoting epithelial–mesenchymal transition, invasion and tumour angiogenesis. Therapeutic strategies targeting FGFs and FGFRs in human cancer are therefore currently being explored. In the present review we will give an overview of FGF signalling, the main FGFR alterations found in human cancer to date, how they may contribute to specific cancer types and strategies for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–352 of 352
Bernard‐Pierrot, I., Gruel, N., Stransky, N., Vincent‐Salomon, A., Reyal, F., Raynal, V., Vallot, C., Pierron, G., Radvanyi, F., & Delattre, O. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1360 · Cited by 103
Genetic Alterations in the Tyrosine Kinase Transcriptome of Human Cancer Cell Lines
Ruhe, J. E., Streit, S., Hart, S., Wong, C., Specht, K., Knyazev, P. G., Knyazeva, T., Tay, L. S., Loo, H. L., Foo, P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2703 · Cited by 102
Functional FGFR4 Gly388Arg Polymorphism Predicts Prognosis in Lung Adenocarcinoma Patients
Spinola, M., Leoni, V. P., Pignatiello, C., Conti, B., Ravagnani, F., Pastorino, U., & Dragani, T. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.17.350 · Cited by 102
Fischer, H., Taylor, N., Allerstorfer, S., Grusch, M., Sonvilla, G., Holzmann, K., Setinek, U., Elbling, L., Cantonati, H., Grasl‐Kraupp, B., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0444 · Cited by 102
Fioretos, T., Panagopoulos, I., Lassen, C., Swedin, A., Billström, R., Isaksson, M., Strömbeck, B., Olofsson, T., Mitelman, F., & Johansson, B. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1195 · Cited by 101
Belloni, E., Trubia, M., Gasparini, P., Micucci, C., Tapinassi, C., Confalonieri, S., Nuciforo, P. G., Martino, B., Lo‐Coco, F., Pelicci, P. G., et al. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20144 · Cited by 101
Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma
Keats, J. J., Reiman, T., Belch, A. R., & Pilarski, L. M. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600822128 · Cited by 99
Resistance to Chemotherapy Is Associated with Fibroblast Growth Factor Receptor 4 Up-Regulation
Roidl, A., Berger, H.-J., Kumar, S., Bange, J., Knyazev, P. G., & Ullrich, A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0890 · Cited by 99
Leung, H. Y., Gullick, W. J., & Lemoine, N. R. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590515 · Cited by 98
Mayr, D. C., Kanitz, V., Anderegg, B., Luthardt, B., Engel, J., Löhrs, U., Amann, G., & Diebold, J. (2006) · American Journal of Clinical Pathology · doi:10.1309/n6x5mb24bp42kp20 · Cited by 97
Serizawa, R., Ralfkiær, U., Steven, K. E., Lam, G. W., Schmiedel, S., Schüz, J., Hansen, A., Horn, T. D., & Guldberg, P. (2010) · International Journal of Cancer · doi:10.1002/ijc.25651 · Cited by 97
Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma
Fritzsche, S., Kenzelmann, M., Hoffmann, M. J., Müller, M., Engers, R., Gröne, H., & Schulz, W. A. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01190 · Cited by 97
Altered Fibroblast Growth Factor Receptor 4 Stability Promotes Prostate Cancer Progression
Wang, J., Yu, W., Cai, Y., Ren, C., & Ittmann, M. (2008) · Neoplasia · doi:10.1593/neo.08450 · Cited by 96
Haines, B. P., Wheldon, L. M., Summerbell, D., Heath, J. K., & Rigby, P. W. J. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.04.004 · Cited by 96
Marks, J. L., McLellan, M. D., Zakowski, M. F., Lash, A., Kasai, Y., Broderick, S., Sarkaria, I. S., Ceppa, D. P., Singh, B., Miner, T. L., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000426 · Cited by 96
Ropiquet, F., Giri, D., Kwabi‐Addo, B., Mansukhani, A., & Ittmann, M. (2000) · PubMed · Cited by 94
Zhang, Y., Wang, H., Toratani, S., Sato, J., Kan, M., McKeehan, W. L., & Okamoto, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191377098 · Cited by 94
Zieger, K., Dyrskjøt, L., Wiuf, C., Jensen, J. L., Andersen, C. L., Jensen, K. M., & Orntoft, T. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1130 · Cited by 93
Chase, A., Grand, F., & Cross, N. C. P. (2007) · Blood · doi:10.1182/blood-2007-02-074286 · Cited by 92
Yagasaki, F., Wakao, D., Yokoyama, Y., Uchida, Y., MUROHASHI, I., Kayano, H., Taniwaki, M., Matsuda, A., & Bessho, M. (2001) · PubMed · Cited by 92
Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma
Mao, X., Orchard, G. E., Lillington, D. M., Russell‐Jones, R., Young, B. D., & Whittaker, S. J. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10184 · Cited by 91
Guasch, G., Popovici, C., Mugneret, F., Chaffanet, M., Pontarotti, P., Birnbaum, D., & Pébusque, M. (2002) · Blood · doi:10.1182/blood-2002-02-0577 · Cited by 88
Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours
Sibley, K., Stern, P., & Knowles, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204543 · Cited by 88
Cha, J. Y., Maddileti, S., Mitin, N., Harden, T. K., & Der, C. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803998200 · Cited by 87
Yang, F., Strand, D. W., & Rowley, D. R. (2007) · Oncogene · doi:10.1038/sj.onc.1210663 · Cited by 86
Expression of the FGFR1 gene in human breast‐carcinoma cells
Jacquemier, J. D., Adélaı̈de, J., Parc, P., Penault-Llorca, F. M., Planche, J., deLapeyrière, O., & Birnbaum, D. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590314 · Cited by 86
Wallerand, H. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh275 · Cited by 86
FGF‐8 is involved in bone metastasis of prostate cancer
Valta, M. P., Tuomela, J. M., Bjartell, A. S., Valve, E. M., Väänänen, H. K., & Härkönen, P. L. (2008) · International Journal of Cancer · doi:10.1002/ijc.23422 · Cited by 85
Identification of four new translocations involving FGFR1 in myeloid disorders
Sohal, J., Chase, A., Mould, S. J., Corcoran, M., Oscier, D. G., Iqbal, S., Parker, S. E., Welborn, J. L., Harris, R. I., Martinelli, G., et al. (2001) · Genes Chromosomes and Cancer · doi:10.1002/gcc.1177 · Cited by 85
Larramendy, M. L., Niini, T., Elonen, E., Nagy, B., Ollila, J., Vihinen, M., & Knuutila, S. (2002) · PubMed · Cited by 84
Peng, D., Sugihara, H., Mukaisho, K., et al. (2003) · The Journal of Pathology · doi:10.1002/path.1459 · Cited by 84
Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH
Ishizuka, T., Tanabe, C., Sakamoto, H., Aoyagi, K., Maekawa, M., Matsukura, N., Tokunaga, A., Tajiri, T., Yoshida, T., Terada, M., et al. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00836-7 · Cited by 82
Tsou, A., Wu, K.-M., Tsen, T.-Y., Chi, C., Chiu, J., Lui, W., Hu, C., Chang, C., Chou, C., & Tsai, S. (1998) · Genomics · doi:10.1006/geno.1998.5338 · Cited by 81
Song, Z., Wu, X., Powell, W. C., Cardiff, R. D., Cohen, M. B., Tin, R. T., Matusik, R. J., Miller, G. J., & Roy‐Burman, P. (2002) · PubMed · Cited by 81
Increased expression of fibroblast growth factor 8 in human breast cancer
Marsh, S. K., Bansal, G., Zammit, C., Barnard, R. C., Coope, R. C., Roberts-Clark, D., Gomm, J. J., Coombes, R. C., & Johnston, C. L. (1999) · Oncogene · doi:10.1038/sj.onc.1202392 · Cited by 81
Streit, S., Mestel, D. S., Schmidt, M., Ullrich, A., & Berking, C. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603181 · Cited by 80
Volm, M., Koomägi, R., Mattern, J., & Stammler, G. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00411-x · Cited by 80
The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1
Walz, C., Chase, A., Schoch, C., Weisser, A., Schlegel, F., Hochhaus, A., Fuchs, R. J., Schmitt‐Gräff, A., Hehlmann, R., Cross, N. C. P., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403712 · Cited by 79
Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration
Sonvilla, G., Allerstorfer, S., Heinzle, C. F., Stättner, S., Karner, J., Klimpfinger, M., Wrba, F., Fischer, H., Gauglhofer, C., Spiegl‐Kreinecker, S., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605596 · Cited by 79
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma
Chang, H., Stewart, A. K., Qi, X. Y., Li, Z., Yi, Q. L., & Trudel, S. (2005) · Blood · doi:10.1182/blood-2005-01-0033 · Cited by 79
Theodorou, V., Boer, M., Weigelt, B., Jonkers, J., van der Valk, M. V., & Hilkens, J. (2004) · Oncogene · doi:10.1038/sj.onc.1207816 · Cited by 78
Role of fibroblast growth factor 8 in growth and progression of hormonal cancer
MATTILA, M., & HARKONEN, P. (2007) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2007.04.010 · Cited by 76
Gu, T.-L., Goss, V. L., Reeves, C., Popova, L., Nardone, J., MacNeill, J., Walters, D. K., Wang, Y., Rush, A. J., Comb, M. J., et al. (2006) · Blood · doi:10.1182/blood-2006-06-026666 · Cited by 76
FGFR3 mutations in prostate cancer: association with low-grade tumors
Hernandez, S. F., de Muga, S., Agell, L., Juanpere-Rodero, N., Esgueva, R., Lorente, J. A., Mojal, S., Serrano, S., & Lloreta, J. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.46 · Cited by 75
Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma
Nord, H., Segersten, U., Sandgren, J., Wester, K., Busch, C., Menzel, U., Komorowski, J., Dumanski, J. P., Malmström, P., & de Ståhl, T. D. (2009) · International Journal of Cancer · doi:10.1002/ijc.24954 · Cited by 75
Persson, F., Winnes, M., Andrén, Y., Wedell, B., Dahlenfors, R., Asp, J., Mark, J., Enlund, F., & Stenman, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210961 · Cited by 75
Dønnem, T., Al-Shibli, K. I., Al‐Saad, S., Busund, L., & Bremnes, R. M. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31819f2e38 · Cited by 75
Adar, R., Ornan, E. M., David, P., & Yayon, A. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.5.860 · Cited by 75
Growth factors in the fetal and neonatal lung
Vasanth, H. K. (2004) · Frontiers in bioscience · doi:10.2741/1245 · Cited by 73
Xian, W., Pappas, L., Pandya, D., Selfors, L. M., Derksen, P. W. B., de Bruin, M., Gray, N. S., Jonkers, J., Rosen, J. M., & Brugge, J. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3398 · Cited by 73
Murphy, T., Darby, S., Mathers, M. E., & Gnanapragasam, V. J. (2009) · The Journal of Pathology · doi:10.1002/path.2657 · Cited by 73
Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells
Pardo, O. E., Arcaro, A., Salerno, G., Tetley, T. D., Valovka, T., Gout, I. T., & Seckl, M. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204994 · Cited by 72
d'AVIS, P. Y., Robertson, S., Meyer, A. L., Bardwell, W., Webster, M. K., & Donoghue, D. J. (1998) · PubMed · Cited by 72
Gutiérrez, N. C., López-Pérez, R., Hernández, J. M., Isidro, I., González, B., Delgado, M., Fermiñán, E., García, J. L., Vázquez, L., González, M., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403625 · Cited by 71
Gruel, N., Lucchesi, C., Raynal, V., Rodrigues, M., Pierron, G., Goudefroye, R., Cottu, P., Reyal, F., Sastre-Garau, X., Fourquet, A., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.05.013 · Cited by 70
Valve, E. M., Nevalainen, M. T., Nurmi, M. J., Laato, M. K., MARTIKAINEN, P. M., & HARKONEN, P. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780291 · Cited by 70
Andrade, V. C. D. C., Parise, O., Hors, C. P., Martins, P. C. D. M., Silva, A. P., & Garicochea, B. (2006) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2006.05.003 · Cited by 69
Extended-Synaptotagmin-2 Mediates FGF Receptor Endocytosis and ERK Activation In Vivo
Jean, S., Mikryukov, A. A., Tremblay, M. G., Baril, J., Guillou, F., Bellenfant, S., & Moss, T. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.08.007 · Cited by 69
The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells
Roidl, A., Foo, P., Wong, W., Mann, C., Bechtold, P. D. S., Berger, H.-J., Streit, S., Ruhe, J. E., Hart, S., Ullrich, A., et al. (2009) · Oncogene · doi:10.1038/onc.2009.432 · Cited by 67
Dellacono, F. R., Spiro, J. D., Eisma, R. J., & Kreutzer, D. L. (1997) · The American Journal of Surgery · doi:10.1016/s0002-9610(97)00169-4 · Cited by 67
Miyake, M., Ishii, M., Koyama, N., Kawashima, K., Kodama, T., Anai, S., Fujimoto, K., Hirao, Y., & Sugano, K. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162768 · Cited by 67
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)
Intini, D., Baldini, L., Fabris, S., Lombardi, L., Ciceri, G., Maiolo, A. T., & Neri, A. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02957.x · Cited by 66
Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy
Kim, H. K., Choi, I. J., Kim, C. G., Kim, H. S., Oshima, A., Yamada, Y., Arao, T., Nishio, K., Michalowski, A. M., & Green, J. E. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.87 · Cited by 65
Guddo, F., Fontanini, G., Reina, C., Vignola, A. M., Angeletti, A., & Bonsignore, G. (1999) · Human Pathology · doi:10.1016/s0046-8177(99)90139-9 · Cited by 65
Yamayoshi, T., Nagayasu, T., Matsumoto, K., Abo, T., Hishikawa, Y., & Koji, T. (2004) · Journal of Pathology · doi:10.1002/path.1617 · Cited by 63
Vékony, H., Ylstra, B., Wilting, S. M., Meijer, G. A., van de Wiel, M. A., Leemans, C. R., van der Waal, I., & Bloemena, E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2555 · Cited by 63
Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer
Pandith, A. A., Shah, Z. A., & Siddiqi, M. A. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.07.014 · Cited by 62
Ollendorff, V., Guasch, G., Isnardon, D., Galindo, R., Birnbaum, D., & Pébusque, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.38.26922 · Cited by 61
Goldstein, M., Meller, I., & Orr‐Urtreger, A. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20489 · Cited by 61
Ueki, T., Koji, T., Tamiya, S., Nakane, P. K., & Tsuneyoshi, M. (1995) · The Journal of Pathology · doi:10.1002/path.1711770405 · Cited by 61
Schaaf, G., Ruijter, J. M., van Ruissen, F., Zwijnenburg, D. A., Waaijer, R., Valentijn, L. J., Benit-Deekman, J., van Kampen, A. H. C., Baas, F., & Kool, M. (2005) · The FASEB Journal · doi:10.1096/fj.04-2104fje · Cited by 60
Zhen, Y., Sørensen, V., Jin, Y., Suo, Z., & Więdłocha, A. (2007) · Oncogene · doi:10.1038/sj.onc.1210473 · Cited by 60
Giatromanolaki, A. N., Koukourakis, M. I., Sivridis, E., O'Byrne, K. J., Cox, G., Thorpe, P. E., Gatter, K. C., & Harris, A. L. (2000) · PubMed · Cited by 60
Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma
Qiu, W.-H. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i34.5266 · Cited by 60
Ågerstam, H., Lilljebjörn, H., Lassen, C., Swedin, A., Richter, J., Vandenberghe, P., Johansson, B., & Fioretos, T. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20442 · Cited by 59
Wasąg, B., Lierman, E., Meeus, M., Cools, J., & Vandenberghe, P. (2011) · Haematologica · doi:10.3324/haematol.2010.036558 · Cited by 59
Guasch, G., Ollendorff, V., Borg, J., Birnbaum, D., & Pébusque, M. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.23.8129-8142.2001 · Cited by 59
Amann, T., Bataille, F., Spruß, T., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090356 · Cited by 59
Otsuki, T., Yamada, O., Yata, K., Sakaguchi, H., Kurebayashi, J., Nakazawa, N., Taniwaki, M., Yawata, Y., & Ueki, A. (1999) · International Journal of Oncology · doi:10.3892/ijo.15.6.1205 · Cited by 58
Hase, T., Kawashiri, S., Tanaka, A., Nozaki, S., Noguchi, N., Kato, K., Nakaya, H., & Nakagawa, K. (2006) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2006.00397.x · Cited by 58
Keratinocyte Growth Factor Receptor Ligands Target the Receptor to Different Intracellular Pathways
Belleudi, F., Leone, L., Nobili, V., Raffa, S., Francescangeli, F., Maggio, M., Morrone, S., Marchese, C., & Torrisi, M. R. (2007) · Traffic : the International Journal of Intracellular Transport · doi:10.1111/j.1600-0854.2007.00651.x · Cited by 58
Wakulich, C. A., Jackson‐Boeters, L., Daley, T. D., & Wysocki, G. P. (2002) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1067/moe.2002.124461 · Cited by 58
Heiskanen, M., Kononen, J., Barlund, M. T., Torhorst, J. K. H., Sauter, G., Kallioniemi, A. H., & Kallioniemi, O. (2001) · Analytical Cellular Pathology · doi:10.1155/2001/981218 · Cited by 58
Aberrant Receptor Signaling and Trafficking as Mechanisms in Oncogenesis
Rusten, T. E., Haglund, K., & Stenmark, H. (2007) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v13.i1.20 · Cited by 58
Self-citationFGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1α
Shah, R. N. H., Ibbitt, J. C., Alitalo, K. K., & Hurst, H. C. (2002) · Oncogene · doi:10.1038/sj.onc.1206020 · Cited by 58
Hidalgo-Curtis, C., Chase, A., Drachenberg, M. R., Roberts, M. W., Finkelstein, J. Z., Mould, S. J., Oscier, D. G., Cross, N. C. P., & Grand, F. (2008) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20541 · Cited by 57
Ren, M., Li, X., & Cowell, J. K. (2009) · Blood · doi:10.1182/blood-2009-03-212704 · Cited by 57
Vizmanos, J. L., Hernández, R. S., Vidal, M. J., Larráyoz, M. J., Odero, M. D., Marín, J., Ardanaz, M. T., Calasanz, M. J., & Cross, N. C. P. (2004) · The Hematology Journal · doi:10.1038/sj.thj.6200561 · Cited by 56
Takanami, I., Tanaka, F., Hashizume, T., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00620-6 · Cited by 55
Mardakheh, F. K., Yekezare, M., Machesky, L. M., & Heath, J. K. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200905118 · Cited by 55
Sugiyama, N., Varjosalo, M. T., Meller, P., Lohi, J., Hyytiäinen, M. M., Kilpinen, S. K., Kallioniemi, O., Ingvarsen, S., Engelholm, L. H., Taipale, J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1223 · Cited by 55
Constitutive activating mutation of theFGFR3b in oral squamous cell carcinomas
Zhang, Y., Hiraishi, Y., Wang, H., Sumi, K., Hayashido, Y., Toratani, S., Kan, M., Sato, J., & Okamoto, T. (2005) · International Journal of Cancer · doi:10.1002/ijc.21145 · Cited by 54
Fabris, S., Agnelli, L., Mattioli, M., Baldini, L., Ronchetti, D., Morabito, F., Verdelli, D., Nobili, L., Intini, D., Callea, V., et al. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20123 · Cited by 53
Sugiyama, N., Varjosalo, M. T., Meller, P., Lohi, J., Chan, K. M., Zhou, Z., Alitalo, K. K., Taipale, J., Keski‐Oja, J., & Lehti, K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914459107 · Cited by 51
Mhawech-Fauceglia, P. Y., Fischer, G., Alvarez, V., et al. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07090.x · Cited by 50
LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome
Soler, G., Nusbaum, S., Varet, B. R., Macintyre, E. A., Vekemans, M. J. J., Romana, S. P., & Radford‐Weiss, I. (2009) · Leukemia · doi:10.1038/leu.2009.79 · Cited by 50
Inferring the functional effects of mutation through clusters of mutations in homologous proteins
Yue, P., Forrest, W. F., Kaminker, J. S., Lohr, S., Zhang, Z., & Cavet, G. (2010) · Human Mutation · doi:10.1002/humu.21194 · Cited by 49
FGFR4 transmembrane domain polymorphism and cancer risk: A meta-analysis including 8555 subjects
Xu, W., Li, Y., Wang, X., Chen, B., Wang, Y., Liu, S., Xu, J., Zhao, W., & Wu, J. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.06.017 · Cited by 49
FGFR1 and WT1 are markers of human prostate cancer progression
Devilard, E., Bladou, F., Ramuz, O., Karsenty, G., Dalès, J.-P., Gravis, G., Nguyen, C., Bertucci, F., Xerri, L., & Birnbaum, D. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-272 · Cited by 46
Jayson, G. C., Vivès, C., Paraskeva, C., Schofield, K. P., Coutts, J., Fleetwood, A., & Gallagher, J. T. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990719)82:2<298::aid-ijc23>3.0.co;2-9 · Cited by 46
Kornmann, M., Ishiwata, T., Matsuda, K., Lopez, M. E., Fukahi, K., Asano, G., Beger, H. G., & Korc, M. (2002) · Gastroenterology · doi:10.1053/gast.2002.34174 · Cited by 45
Gravdal, K., HALVORSEN, O. J., Haukaas, S. A., & Akslen, L. A. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-0075-3 · Cited by 45
Expression of Basic Fibroblast Growth Factor, its Receptors and Syndecans in Bladder Cancer
Marzioni, D., Lorenzi, T., Roberta Mazzucchelli, A., Capparuccia, L., Morroni, M., Fiorini, R., Bracalenti, C., Catalano, A., David, G., Castellucci, M., et al. (2009) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200902200308 · Cited by 44
Guasch, G., Delaval, B., Arnoulet, C., Xie, M.-J., Xerri, L., Sainty, D., Birnbaum, D., & Pébusque, M. (2003) · Blood · doi:10.1182/blood-2003-05-1690 · Cited by 44
Reciprocal relationship in gene expression between FGFR1 and FGFR3: implication for tumorigenesis
Jang, J. (2004) · Oncogene · doi:10.1038/sj.onc.1208254 · Cited by 42
Mao, X., Onadim, Z., Price, E. A., Child, F. J., Lillington, D. M., Russell‐Jones, R., Young, B. D., & Whittaker, S. J. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12406.x · Cited by 42
Shingū, K., FUJIMORI, M., Ito, K., et al. (1998) · Endocrine Journal · doi:10.1507/endocrj.45.35 · Cited by 41
FGFR2 mutations are rare across histologic subtypes of ovarian cancer
Byron, S. A., Gartside, M. G., Wellens, C. L., Goodfellow, P. J., Birrer, M. J., Campbell, I., & Pollock, P. M. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.12.002 · Cited by 41
FGFR3 gene mutations associated with human skeletal disorders occur rarely in multiple myeloma.
Fracchiolla, N., Luminari, S., Baldini, L., Lombardi, L., Maiolo, A., & Neri, A. (1998) · Blood · doi:10.1182/blood.v92.8.2987 · Cited by 40
A molecular study of the t(4;14) in multiple myeloma
Sibley, K., Fenton, J. A. L., Dring, A. M., Ashcroft, A. J., Rawstron, A. C., & Morgan, G. J. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03618.x · Cited by 39
Maruyama‐Takahashi, K., Shimada, N., Imada, T., Maekawa‐Tokuda, Y., Ishii, T., Ouchi, J., Kusaka, H., Miyaji, H., Akinaga, S., Tanaka, A., et al. (2008) · The Prostate · doi:10.1002/pros.20728 · Cited by 38
Krejci, P., Murakami, S., Procházková, J., Trantírek, L., Chlebová, K., Ouyang, Z.-F., Aklian, A., Smutny, J., Bryja, V., Kozubík, A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.083626 · Cited by 38
Wu, R., Connolly, D., Ngelangel, C., Bosch, F., Muñoz, N., & Cho, K. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203934 · Cited by 37
Falvella, F. S., Frullanti, E., Galvan, A., Spinola, M., Noci, S., Cecco, L. D., Nosotti, M., Santambrogio, L., Incarbone, M., Alloisio, M., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24302 · Cited by 36
Xu, B., Tong, N., Chen, S. Q., Li, H., Wang, Z. J., Zhang, Z. D., & Chen, M. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-84 · Cited by 36
Elo, T., Valve, E. M., Seppänen, J., Vuorikoski, H., Mäkelä, S., POUTANEN, M. H., Kujala, P. M., & Härkönen, P. L. (2010) · Neoplasia · doi:10.1593/neo.10776 · Cited by 35
Trade, Human Rights and an Alternative World Order: The role of civil society
Pitanguy, J., & Heringer, R. R. (2002) · Development · doi:10.1057/palgrave.development.1110350 · Cited by 35
Expression of FGF1 and FGFR1 in human melanoma tissues
Xerri, L., Battyáni, Z., Grob, J., Parc, P., Hassoun, J., Bonerandi, J. J., & Birnbaum, D. (1996) · Melanoma Research · doi:10.1097/00008390-199606000-00005 · Cited by 33
Naito (2010) · International Journal of Oncology · doi:10.3892/ijo_00000832 · Cited by 33
Martinez, N. J., García-Domínguez, C. A., Domingo, B., Oliva, J. L., Zarich, N., Sánchez, A., Gutiérrez-Eisman, S., Llopis, J., & Rojas, J. M. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.07.008 · Cited by 32
Darby, S., Murphy, T., Thomas, H. C., Robson, C. N., Leung, H. Y., Mathers, M. E., & Gnanapragasam, V. J. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605379 · Cited by 32
Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis
FitzGerald, L. M., Karlins, E., Karyadi, D. M., Kwon, E. M., Koopmeiners, J. S., Stanford, J. L., & Ostrander, E. A. (2008) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2008.46 · Cited by 32
SomaticFGF9mutations in colorectal and endometrial carcinomas associated with membranousβ-catenin
Abdel‐Rahman, W. M., Kalinina, J., Shoman, S., Eissa, S., Ollikainen, M., Elomaa, O., Eliseenkova, A. V., Bützow, R. C., Mohammadi, M., & Peltomäki, P. (2007) · Human Mutation · doi:10.1002/humu.20653 · Cited by 32
Matsunobu, T., Ishiwata, T., Yoshino, M., Watanabe, M., Kudo, M., Matsumoto, K., Tokunaga, A., Tajiri, T., & Naito, Z. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.2.307 · Cited by 31
The Fibroblast Growth Factor Receptor-4 Arg388 Allele is Associated with Gastric Cancer Progression
Ye, Y.-W., Shi, Y.-Q., Zhou, Y., Du, C., Wang, C.-M., Zhan, H.-Q., Zheng, B., Cao, X., Sun, M.-H., & Fu, H. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1323-6 · Cited by 31
Nakamura, N., Iijima, T., Mase, K., Furuya, S., Kano, J., Morishita, Y., & Noguchi, M. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02207.x · Cited by 31
Castro-Feijóo, L., Loidi, L., Vidal, A., Parajes, S., Rosón, E., Álvarez, A., Cabanas, P., Barreiro, J., Alonso, A. X. M. D. A., Domı́nguez, F., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0393 · Cited by 31
Tanuma, J., Izumo, T., Hirano, M., Oyazato, Y., Hori, F., Umemura, E., Shisa, H., Hiai, H., & Kitano, M. (2010) · Oncology Reports · doi:10.3892/or_00000692 · Cited by 29
A biphenotypic transformation of 8p11 myeloproliferative syndrome with CEP1/FGFR1 fusion gene
Yamamoto, K., Kawano, H., Nishikawa, S., Yakushijin, K., Okamura, A., & Matsui, T. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00723.x · Cited by 27
Fibroblast growth factor receptor 4 mutation and polymorphism in Japanese lung cancer
Sasaki (1994) · Oncology Reports · doi:10.3892/or_00000119 · Cited by 26
Hansen, R. M. S., Goriely, A., Wall, S. A., Roberts, I. S. D., & Wilkie, A. O. M. (2005) · The Journal of Pathology · doi:10.1002/path.1816 · Cited by 26
Schaefer, K., Wai, D., Poremba, C., Korsching, E., van Valen, F., Ozaki, T., Boecker, W., & Dockhorn‐Dworniczak, B. (2002) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-001-0558-9 · Cited by 26
Nakazawa, N., Nishida, K., Tamura, A., Kobayashi, M., Iwai, T., Horiike, S., Nishigaki, H., Otsuki, T., Tomiyama, Y., Fujii, H., et al. (2000) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(99)00155-7 · Cited by 26
Mozziconacci, J., Carbuccia, N., Prébet, T., Charbonnier, A., Murati, A., Vey, N., Chaffanet, M., & Birnbaum, D. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.11.012 · Cited by 25
Activation of fibroblast growth factor receptor 3 and oncogene-induced senescence in skin tumours
Hida, Y., Kubo, Y., & Arase, S. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09068.x · Cited by 24
Park, T. S., Song, J., Kim, J. S., Yang, W. I., Song, S., Kim, S. J., Suh, B., & Choi, J. R. (2008) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2007.11.011 · Cited by 24
Chou, A. Y., Dekker, N. P., & Jordan, R. C. (2009) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2008.12.050 · Cited by 23
ErbB2 and TGF-beta: A Cooperative Role in Mammory Tumor Progression?
Seton-Rogers, S. E., & Brugge, J. S. (2004) · Cell Cycle · doi:10.4161/cc.3.5.886 · Cited by 22
Etienne, A., Gelsi‐Boyer, V., Carbuccia, N., Adélaïde, J., Barba, G., Starza, R. L., Murati, A., Éclache, V., Birg, F., Birnbaum, D., et al. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.10.004 · Cited by 22
Shimada, N., Ishii, T., Imada, T., Takaba, K., Sasaki, Y., Maruyama‐Takahashi, K., Maekawa‐Tokuda, Y., Kusaka, H., Akinaga, S., Tanaka, A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2358 · Cited by 22
Wong, W., Cheng, K. C. K., Lau, K., Chan, N. P.-H., Shing, M. M. K., Cheng, S., Chik, K.-W., Li, C. K., & Ng, M. H. L. (2006) · Leukemia Research · doi:10.1016/j.leukres.2006.04.015 · Cited by 22
Use of protein array to investigate receptor tyrosine kinases activated in gastric cancer
Masaki, M. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000480 · Cited by 20
A Therapeutic Target for Smoking-Associated Lung Cancer
Turner, N. C., & Seckl, M. J. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001942 · Cited by 20
Sasaki, T., Arai, H., Beppu, T., & Ogasawara, K. (2003) · Brain Tumor Pathology · doi:10.1007/bf02483448 · Cited by 19
Kasyapa, C. S., Gu, T., Natarajan, L., Polakiewicz, R. D., & Cowell, J. K. (2009) · PROTEOMICS · doi:10.1002/pmic.200800852 · Cited by 19
Hamaguchi, A., Tooyama, I., Yoshiki, T., & Kimurâ, H. (1995) · The Prostate · doi:10.1002/pros.2990270304 · Cited by 18
Hrs regulates the endocytic sorting of the fibroblast growth factor receptor 2b
Belleudi, F., Leone, L., Maggio, M., & Torrisi, M. R. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.03.022 · Cited by 18
Yu, S., Zheng, L., Ladanyi, M., Asa, S. L., & Ezzat, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0223 · Cited by 17
Matsumoto, K., Morita, K., Takada, S., Sakura, T., Shiozaki, H., Murakami, H., & Miyawaki, S. (1999) · PubMed · Cited by 16
Dekker, P. B. D., Kuipers‐Dijkshoorn, N. J., Baelde, H. J., van der Mey, A. G. L., Hogendoorn, P. C. W., & Cornelisse, C. J. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.06.013 · Cited by 15
Generation of Monoclonal Antibody Targeting Fibroblast Growth Factor Receptor 3
Gorbenko, O., Ovcharenko, G., Klymenko, T., Zhyvoloup, O. M., Gaman, N., Volkova, D., Gout, I. T., & Filonenko, V. V. (2009) · Hybridoma · doi:10.1089/hyb.2009.0018 · Cited by 15
O’Toole, S. A., DUNN, E., SHEPPARD, B. L., Klocker, H., Bektić, J., Smyth, P. C., Martin, C. M., Sheils, O. M., & O’Leary, J. J. (2006) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2006.00530.x · Cited by 12
Cited by
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
Singh, D., Chan, J. M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E. M., Reichel, J., Porrati, P., Pellegatta, S., et al. (2012) · Science · doi:10.1126/science.1220834 · Cited by 789
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Kalyana-Sundaram, S., Khazanov, N., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S.-F., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 744
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors
Roskoski, R. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.01.003 · Cited by 607
Targeting FGFR Signaling in Cancer
Touat, M., Ileana, E., Postel-Vinay, S., André, F., & Soria, J.-C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2329 · Cited by 524
Current developments of coumarin-based anti-cancer agents in medicinal chemistry
Emami, S., & Dadashpour, S. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.08.033 · Cited by 504
Metadata
- Authors
- Wesche, J., Haglund, K., & Haugsten, E. M.
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 2011-06-28
- Volume
- 437
- Issue
- 2
- Pages
- 199-213
- ISSN
- 0264-6021 (ISSN-L)
- 1470-8728
- OpenAlex
- W2113727201
- Cited by
- 534
- References
- 352
- FWCI
- 17.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.